Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

57results about How to "Pharmacological effect is clear" patented technology

Drug for treating coronary heart disease

The invention discloses a drug for treating coronary heart disease, which comprises 230 of salvia, 70 of piper longum, 115 of aquilaria, 51 of rosewood, 76 of nutmeg, 38 of kaempferol, 76 of wide jujube, 25 of sandalwood, 76 of sea buckthorn, and 25 of red sandal according to the weight ratio. The salvia, the piper longum, the kaempferol, the wide jujube, the sea buckthorn, and the nutmeg are extracted for three times; for the first time, 14 times of 75 percent of ethanol are added and heated with 2 hours of reflux; for the second time, 12 times of 75 percent of ethanol are added and heated with 2 hours of reflux; for the third time, 10 times of 75 percent of ethanol are added and heated with 2 hours of reflux and the ethanol is recycled. After the coarse powder of aquilaria, rosewood, red sandal and sandalwood are immersed into 8 times of water for 5 hours, volatile oil is extracted for twice with 14 hours for each time; the water extract liquid of the volatile oil is filtered; the herb residue is added with 8 times of water and then heated and recycled for 2 hours, and then filtered; later the extract liquid is merged, concentrated, and dried for obtaining cream powder. By crushing the cream powder into fine powder and then mixing evenly the powder, later adding suitable amount of PEG-6000 for melting and then adding the volatile oil, dropping pills are then made.
Owner:INNER MONGOLIA TIANQI HAN&MONGOLIA PHARMA CO

Medicated diet and dietary therapy composition for type 2 diabetes and preparation method of medicated diet and dietary therapy composition

The invention provides a medicinal diet and dietary therapy composition for type 2 diabetes. The medicinal diet and dietary therapy composition is prepared from the following raw materials in parts byweight: 1-15 parts of horseradish tree leaves, 1-10 parts of roselle, 1-15 parts of mulberry leaves, 1-30 parts of Chinese yams, 1-15 parts of polygonatum kingianum, 1-12 parts of polygonatum odoratum, 1-15 parts of pueraria mirifica, 1-12 parts of common cephalanoplos herbs, 1-20 parts of fructus phyllanthi, 1-10 parts of symphytum asperum, 1-12 parts of coriandrum sativum, 1-15 parts of burdockroots, 1-12 parts of smoked plums, 1-6 parts of cinnamon, 1-10 parts of pine pollen and 0.1-1 part of chitosan oligosaccharide. The invention further provides a preparation method of the medicated diet and dietary therapy composition for the type 2 diabetes. The medicated diet and dietary therapy composition for type 2 diabetes is definite in curative effects, clear in action targets and pharmacological effects, wide in raw material source, low in cost, simple in preparation method and capable of dissolving turbidity, reducing blood glucose, tonifying spleen, nourishing pancreas, preventing and treating hyperglycemia and the type 2 diabetes.
Owner:SHENZHEN ELDERLY MEDICAL RES INST +1

Xuesaitong pharmaceutical composition and preparation method, preparation and application thereof

The invention discloses a Xuesaitong pharmaceutical composition and a preparation method, a preparation and application thereof. The Xuesaitong pharmaceutical composition is prepared from the following components in percentage by mass: 0.001 to 99.996% of ginsenoside Rb2, 0.001 to 99.996% of ginsenoside Rb1, 0.001 to 99.996% of ginsenoside Rg1, 0.001 to 99.996% of ginsenoside Rc, and 0.001 to 99.996% of notoginsenoside R1. The Xuesaitong pharmaceutical composition and the preparation have the advantages that the obvious treatment effect on ischemic cardiovascular and cerebrovascular diseases of myocardial infarction, cerebral apoplexy, cerebral infarction, brain hemiplegia and the like, and the retinopathy or optic nerve injury disease due to ischemic cardiovascular and cerebrovascular diseases, diabetes and the like is realized, and the application prospect is broad; compared with the prior art and the product, the treatment effect is better, the safety is higher, and the requirementof clinical medicine usage can be well met; the technology of the preparation method is simple, the conditions are mild, the operation is convenient, the quality is stable and controllable, and the preparation method is suitable for industrialized large-scale production.
Owner:KPC PHARM INC

Natural product anti-inflammation medicine composition and use thereof

The invention relates to a natural product anti-inflammation medicine composition and a use thereof. Every dosage unit includes 0.7-3.0g of ligustrazine, 0.1-1.1g of resveratrol and 1.7-11.7g of curcumin, and the dosage unit is the total amount of the above medicine precision used every day. The medicine composition adopting ligustrazine, resveratrol and curcumin as active components is prepared through directly physically mixing 0.7-3.0g of ligustrazine, 0.1-1.1g of resveratrol and 1.7-11.7g of curcumin, or a pharmaceutically acceptable carrier is added to make the total weight of ligustrazine, resveratrol and curcumin account for 0.5-40% of the total weight of the medicine composition in order to prepare any clinically acceptable oral dosage form. The invention also provides a use of the medicine composition adopting the ligustrazine, resveratrol and curcumin as active components in the preparation of anti-inflammation medicines. The medicine composition adopting the ligustrazine, resveratrol and curcumin as active components has the characteristics of simple preparation method, convenient quality control, high efficiency and low toxicity, and can be used to treat pneumonia, hepatitis, nephritis, arthritis, pyohemia, ulcerative colitis, asthma, atherosclerosis and other clinic common inflammation diseases.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

Traditional Chinese medicine composition for treating stroke, middle meridian, coronary heart disease and angina pectoris caused by obstruction of collaterals by blood stasis and preparation method of traditional Chinese medicine composition

The invention relates to the technical field of medicine extraction, in particular to a traditional Chinese medicine composition for treating stroke, middle meridian, coronary heart disease and anginapectoris caused by obstruction of collaterals by blood stasis and a preparation method thereof. On the basis of compatibility of Shexiang Xinnaotong Jiaonang, effective parts of medicinal materials are enriched, separated and purified, components are screened, different extraction parts are re-compatible to form a new prescription, and the Chinese patent medicine with basically clear material basis, clear action mechanism and more accurate clinical indications is developed. It is shown by research by pharmacodynamic contrast, the effect of the traditional Chinese medicine composition is obviously superior to that of a control group; the traditional Chinese medicine composition can increase coronary blood flow, protect ischemic myocardial injury, adjust lipid peroxidation reaction, improvebrain tissue blood flow and neurotrophy and inhibit brain tissue apoptosis, has a definite pharmacological effect on stroke, middle and collateral channels, coronary heart disease, angina pectoris and the like caused by blood stasis blocking collaterals, and is remarkable in effect.
Owner:吉林修正药业新药开发有限公司 +1

A Xuesaitong pharmaceutical composition and its preparation method, preparation and application

The invention discloses a Xuesaitong pharmaceutical composition, its preparation method, preparation and application. The Xuesaitong pharmaceutical composition includes the following pharmaceutical components in mass percentage: 0.001-99.996% of ginsenoside Rb2, 0.001-99.996% of ginsenoside Rb1, 0.001-99.996% of ginsenoside Rg1, 0.001-99.996% of ginsenoside Rc and Notoginsenoside R1 0.001~99.996%. The pharmaceutical composition of the present invention and its preparation are effective for myocardial infarction, cerebral apoplexy, cerebral infarction, cerebral hemiplegia and other ischemic cardiovascular and cerebrovascular diseases, as well as retinopathy or optic nerve damage caused by ischemic cardiovascular and cerebrovascular diseases, diabetes and other reasons. Significant curative effect, has broad application prospects. Compared with the prior art and products, the Xuesaitong medicinal composition and its preparations of the present invention have better curative effect and higher safety, and can better meet the requirements of clinical medication. The preparation method provided by the invention has simple process, mild conditions, convenient operation, stable and controllable quality, and is suitable for large-scale industrial production.
Owner:KPC PHARM INC

Application of glibenclamide in preparing medicines for preventing and protecting radiation-induced pulmonary injury

The invention relates to the technical field of medicines, and provides an application of glibenclamide or derivatives thereof in preparing medicines for preventing and protecting radiation-induced pulmonary injury. Furthermore, the invention also provides a pharmaceutical composition for preventing and protecting the radiation-induced pulmonary injury, wherein the pharmaceutical composition consists of the glibenclamide or derivatives thereof and pharmaceutically acceptable adjuvants. Based upon mice in-vivo experiments, the glibenclamide can obviously relieve a damage degree of blood vessel endothelium caused by radiation, so that increase in erythrocyte effusion is inhibited and the circumstance of pulmonary hemorrhage after the radiation is relieved; and through in-vivo cytological experiments, the glibenclamide can reduce an apoptosis rate of cells which accept the radiation and improve the circumstance of proliferation inhibition, showing that the glibenclamide, when applied in previous ways, can relieve the radiation-induced pulmonary injury of mice and reduce sensitivity of vascular endothelial cells to radiation; therefore, a new evidence is provided for prevention and protection of the radiation-induced pulmonary injury by virtue of the glibenclamide or derivatives thereof.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products